Abstract: The RAS family of oncoproteins, particularly KRAS, are critical drivers of aggressive malignancies, including colorectal cancer (CRC). Historically considered "undruggable," recent therapeutic breakthroughs have led to the development of mutation-specific inhibitors, though their clinical utility is often limited by narrow mutational coverage and the rapid emergence of resistance. Daraxonrasib (RMC-6236) represents a paradigm shift as a first-in-class, orally bioavailable, broad-spectrum pan-RAS(ON) multi-selective inhibitor. By forming a unique noncovalent tri-complex with cyclophilin A (CypA) and the active GTP-bound state of RAS, RMC-6236 effectively silences downstream oncogenic signaling across multiple RAS variants. This literature review synthesizes current research on Daraxonrasib, detailing its pharmacological activity, molecular mechanism of action, structure-activity relationships, current limitations, and future perspectives, with a specific focus on its therapeutic potential and ongoing clinical evaluation in colorectal cancer.
1. Introduction
The RAS family of proto-oncogenes (KRAS, HRAS, and NRAS) encodes small GTPase proteins that act as molecular switches regulating cell growth, survival, and proliferation [2]. Activating mutations in these genes, particularly KRAS, are highly prevalent in aggressive solid tumors, including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), where KRAS mutations account for approximately 40% of cases [2]. For decades, targeting mutant RAS was challenging due to the lack of suitable binding pockets on the protein surface. While recent FDA approvals of KRAS G12C-specific inhibitors (such as sotorasib and adagrasib) marked a significant breakthrough, these agents are limited to a specific mutation that represents only a fraction of RAS-driven cancers and are prone to acquired resistance [1][2].
To address the limitations of allele-specific inhibitors, research has shifted toward broad-spectrum pan-RAS inhibitors. Daraxonrasib (RMC-6236) has emerged as a highly promising multi-selective inhibitor that targets the active GTP-bound state of multiple RAS isoforms and mutations [1][2]. By providing broader coverage of KRAS mutations (including G12D, G12V, and others common in CRC), RMC-6236 offers a novel therapeutic strategy for patients with historically recalcitrant RAS-addicted cancers [1][3].
2. Pharmacological Activity
Daraxonrasib (RMC-6236) demonstrates potent preclinical and early clinical antitumor activity across a wide range of KRAS-mutated models. Unlike earlier inhibitors that trap RAS in its inactive state, RMC-6236 induces durable tumor regression across multiple KRAS G12X models by targeting the active oncoprotein [3]. Pharmacokinetically, RMC-6236 exhibits excellent tissue distribution; studies in xenograft models reveal that the drug accumulates in tumor tissue at concentrations 3 to 7 times higher than in the blood, and its clearance from tumors is slower than from normal tissues [3]. Furthermore, RMC-6236 is highly permeable and capable of crossing the blood-brain barrier (BBB), expanding its therapeutic utility to patients with CNS involvement [2][3].
In the context of colorectal cancer (CRC) and other gastrointestinal malignancies, RMC-6236 is currently undergoing extensive clinical evaluation. The Phase I trial NCT05379985 is assessing its safety, tolerability, and clinical activity in patients with advanced solid tumors (including CRC) harboring specific RAS mutations [1]. To maximize its pharmacological efficacy in CRC, the Phase I/II trial NCT06445062 is investigating RMC-6236 in combination with standard-of-care (SOC) regimens, including 5-fluorouracil-based therapies, cetuximab, and mFOLFOX6 [1]. Additionally, RMC-6236 is being evaluated in combination with the KRAS G12C-specific inhibitor RMC-6291 in CRC and other solid tumors (NCT06128551) [1]. Beyond direct tumor suppression, RMC-6236 exhibits immunomodulatory activity by remodeling the tumor microenvironment (TME), enhancing the infiltration of CD4+ and CD8+ T cells, increasing MHC class II expression, and reducing immunosuppressive myeloid-derived suppressor cells and M2 macrophages [2].
3. Molecular Mechanism of Action
The molecular mechanism of Daraxonrasib (RMC-6236) represents a fundamental departure from traditional covalent KRAS G12C inhibitors, which target the inactive GDP-bound RAS(OFF) state. RMC-6236 is a nonsteroidal, noncovalent multi-selective inhibitor designed to target the active, GTP-bound form of RAS (RAS(ON)) [1][2].
Mechanistically, RMC-6236 functions as a "molecular glue" that recruits the intracellular chaperone protein cyclophilin A (CypA). The drug binds to CypA, remodeling its surface to create a high-affinity complex. This binary complex subsequently binds to the active RAS-GTP protein, forming a nonproductive ternary (tri-complex) structure: CypA:RMC-6236:RAS-GTP [2][3]. The inhibitor occupies the switch II pocket (SII-P) of the RAS protein, locking it in a conformationally restricted state. By stabilizing this signaling-incompetent configuration, the tri-complex sterically blocks RAS from engaging with its downstream effector proteins, such as PI3K (phosphoinositide 3-kinase), RAF kinases, and RAL-GDS (RAL guanine nucleotide dissociation stimulator). Consequently, this interaction effectively silences the downstream MAPK and PI3K/AKT oncogenic signaling pathways [2].
4. Structure-Activity Relationship (SAR)
The structural design of RMC-6236 enables it to act as a pan-RAS inhibitor by exploiting the conserved switch II pocket across different RAS isoforms and mutational variants. The structure-activity relationship is heavily dependent on the compound's ability to bind CypA with high affinity and subsequently engage the RAS protein. Preclinical binding assays demonstrate that RMC-6236 binds to CypA with a dissociation constant (Kd) of 55.3 nmol/L [3].
Once the RMC-6236–CypA complex is formed, it exhibits potent binding affinities across a spectrum of GTP-bound RAS variants. Specifically, the complex binds to KRAS G12D with a Kd of 131 nmol/L, KRAS G12V with a Kd of 364 nmol/L, and wild-type KRAS with a Kd of 154 nmol/L [3]. This broad binding profile confirms its structural capacity to neutralize multiple oncogenic mutants simultaneously. The ability to engage wild-type RAS also contributes to its broad-spectrum efficacy, though the structural preference for tumor-specific accumulation helps mitigate potential toxicity in healthy tissues [2][3].
5. Current Limitations
Despite its promising efficacy, the clinical application of Daraxonrasib faces several limitations and challenges. First, the broad inhibition of both mutant and wild-type RAS raises concerns regarding on-target toxicity and the disruption of normal tissue homeostasis, as wild-type RAS is essential for normal cellular functions [2]. In early clinical trials, reported adverse events (AEs) included rash, diarrhea, nausea, vomiting, stomatitis, fatigue, paronychia, mucosal inflammation, decreased appetite, and peripheral edema [1]. While Grade 4 AEs are rare, treatment discontinuation due to Grade 3 toxicities (such as rash and gastrointestinal issues) occurs in a subset of patients [2].
Second, adaptive resistance remains a significant hurdle. When RAS signaling is profoundly inhibited by pan-RAS agents, cancer cells can bypass the blockade through compensatory mechanisms. A primary escape route involves the activation of the YAP/TAZ-TEAD transcriptional complex, which promotes cell survival and proliferation by suppressing proapoptotic genes and maintaining downstream PI3K/AKT/mTOR signaling [2]. Additionally, adaptive feedback loops involving upstream receptor tyrosine kinases (RTKs) like EGFR can complicate treatment, particularly in CRC, where EGFR signaling is a known driver of resistance [2].
6. Future Perspectives
To overcome current limitations and maximize the therapeutic potential of Daraxonrasib in CRC and other malignancies, future strategies are heavily focused on rational combination therapies. Because CRC frequently utilizes EGFR-mediated feedback loops to bypass RAS inhibition, combining RMC-6236 with EGFR inhibitors (e.g., cetuximab) and standard chemotherapy (e.g., mFOLFOX6 or 5-fluorouracil) is a highly anticipated approach currently under investigation in the NCT06445062 trial [1].
Furthermore, addressing non-genetic adaptive resistance will be critical. Co-targeting the YAP-TEAD pathway alongside pan-RAS inhibition has shown preclinical promise in bypassing resistance mechanisms and improving therapeutic durability [2]. Additionally, because RMC-6236 favorably remodels the tumor microenvironment by reducing immunosuppressive cells and enhancing T-cell infiltration, combining this agent with immune checkpoint inhibitors (such as anti-PD-1 therapies) represents a strong rationale for achieving synergistic tumor control [2]. Finally, the identification of predictive biomarkers will be essential to select the CRC patient populations most likely to benefit from pan-RAS(ON) tri-complex inhibitors [2].
